Alkermes (ALKS) director logs RSU exercise, tax withholding and new equity grants
Rhea-AI Filing Summary
Alkermes plc. director Wilson Frank Anders reported several routine equity compensation moves. On May 21, 2026, he exercised 6,142 Restricted Stock Units, receiving the same number of ordinary shares, and had 1,475 ordinary shares withheld to cover tax obligations at $36.95 per share. Following these transactions, he directly held 37,226 ordinary shares.
On May 20, 2026, he received a new grant of 5,409 Restricted Stock Units, each representing a contingent right to one ordinary share, and a Non Qualified Stock Option for 11,538 ordinary shares with an exercise price of $36.98 per share, expiring on May 20, 2036. The filing describes these events as grants, vesting, and tax-withholding rather than open-market buying or selling.
Positive
- None.
Negative
- None.
Insights
Routine director equity grants, RSU vesting, and tax withholding.
The transactions show Wilson Frank Anders, a director of Alkermes plc., receiving equity compensation and settling taxes. He exercised 6,142 RSUs into ordinary shares and had 1,475 shares withheld at $36.95 for tax obligations, a standard non-market mechanism.
He also received 5,409 new RSUs and options on 11,538 shares at an exercise price of $36.98, expiring in 2036. These awards align with typical board compensation structures and do not involve open-market purchases or sales, so the informational value for investors is limited and primarily administrative.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit Award | 6,142 | $0.00 | -- |
| Exercise | Ordinary Shares | 6,142 | $0.00 | -- |
| Tax Withholding | Ordinary Shares | 1,475 | $36.95 | $55K |
| Grant/Award | Non Qualified Stock Option (Right to Buy) | 11,538 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit Award | 5,409 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one ordinary share. Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. This award is fully vested in accordance with its terms.